|
1
|
Kajatt Amorin E: Lung cancer: A review of
current knowledge, diagnostic methods and therapeutic perspectives.
Rev Peru Med Exp Salud Publica. 30:85–92. 2013.(In Spanish).
PubMed/NCBI
|
|
2
|
Spaans JN and Goss GD: Drug resistance to
molecular targeted therapy and its consequences for treatment
decisions in non-small-cell lung cancer. Front Oncol. 4:1902014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu ZG, Li MH, Wang JS, Wei DD, Liu QW and
Kong LY: Developmental toxicity and neurotoxicity of two
matrine-type alkaloids, matrine and sophocarpine, in zebrafish
(Danio rerio) embryos/larvae. Reprod Toxicol. 47:33–41. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu YQ, Li Y, Qin J, Wang Q, She YL, Luo
YL, He JX, Li JY and Xie XD: Matrine reduces proliferation of human
lung cancer cells by inducing apoptosis and changing miRNA
expression profiles. Asian Pac J Cancer Prev. 15:2169–2177. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang CL, Liu SS, Ma YG, Liu YY, Xue YX and
Huang B: The influence of intraoperative pleural perfusion with
matrine-cisplatin or cisplatin on stromal cell-derived factor-1 in
non-small cell lung cancer patients with subclinical pleural
metastasis. Med Oncol. 29:574–581. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rogler CE and Chisari FV: Cellular and
molecular mechanisms of hepatocarcinogenesis. Semin Liver Dis.
12:265–278. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dong M, Nio Y, Yamasawa K, Toga T, Yue L
and Harada T: p53 alteration is not an independent prognostic
indicator, but affects the efficacy of adjuvant chemotherapy in
human pancreatic cancer. J Surg Oncol. 82:111–120. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsui TA, Sowa Y, Murata H, Takagi K,
Nakanishi R, Aoki S, Yoshikawa M, Kobayashi M, Sakabe T, Kubo T and
Sakai T: The plant alkaloid cryptolepine induces p21WAF1/CIP1 and
cell cycle arrest in a human osteosarcoma cell line. Int J Oncol.
31:915–922. 2007.PubMed/NCBI
|
|
9
|
Fecteau JF, Corral LG, Ghia EM, Gaidarova
S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B,
Lopez-Girona A, et al: Lenalidomide inhibits the proliferation of
CLL cells via a cereblon/p21 (WAF1/Cip1)-dependent mechanism
independent of functional p53. Blood. 124:1637–1644. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yeo D, He H, Baldwin GS and Nikfarjam M:
The role of p21-activated kinases in pancreatic cancer. Pancreas.
44:363–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xie D, Lan L, Huang K, Chen L, Xu C, Wang
R, Shi Y, Wu X, Wang L, Liu Y and Lu B: Association of p53/p21
expression and cigarette smoking with tumor progression and poor
prognosis in non-small cell lung cancer patients. Oncol Rep.
32:2517–2526. 2014.PubMed/NCBI
|
|
12
|
Freund G, Desplancq D, Stoessel A,
Weinsanto R, Sibler AP, Robin G, Martineau P, Didier P, Wagner J
and Weiss E: Generation of an intrabody-based reagent suitable for
imaging endogenous proliferating cell nuclear antigen in living
cancer cells. J Mol Recognit. 27:549–558. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Halvorsen OJ: Molecular and prognostic
markers in prostate cancer. A study of cell-cycle regulators,
angiogenesis and candidate markers. APMIS. Suppl. 5–62. 2008.
|
|
14
|
Liu Y, Bi T, Wang G, Dai W, Wu G, Qian L,
Gao Q and Shen G: Lupeol inhibits proliferation and induces
apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK
pathways. Naunyn Schmiedebergs Arch Pharmacol. 388:295–304. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chakravarthy R, Clemens MJ, Pirianov G,
Perdios N, Mudan S, Cartwright JE and Elia A: Role of the eIF4E
binding protein 4E-BP1 in regulation of the sensitivity of human
pancreatic cancer cells to TRAIL and celastrol-induced apoptosis.
Biol Cell. 105:414–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martineau Y, Azar R, Müller D, Lasfargues
C, El Khawand S, Anesia R, Pelletier J, Bousquet C and Pyronnet S:
Pancreatic tumours escape from translational control through 4E-BP1
loss. Oncogene. 33:1367–1374. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bi W, Tian M and Row KH: Solid-phase
extraction of matrine and oxymatrine from Sophora flavescens
Ait using amino-imidazolium polymer. J Sep Sci. 33:1739–1745. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cho CH, Chuang CY and Chen CF: Study of
the antipyretic activity of matrine. A lupin alkaloid isolated from
Sophora subprostrata. Planta Med. 343–345. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang H, Guo S, Qian D, Qian Y and Duan JA:
Comparative analysis of quinolizidine alkaloids from different
parts of Sophora alopecuroides seeds by UPLC-MS/MS. J Pharm
Biomed Anal. 67–68:16–21. 2012. View Article : Google Scholar
|
|
21
|
Ou X, Chen Y, Cheng X, Zhang X and He Q:
Potentiation of resveratrol-induced apoptosis by matrine in human
hepatoma HepG2 cells. Oncol Rep. 32:2803–2809. 2014.PubMed/NCBI
|
|
22
|
Niu H, Zhang Y, Wu B, Zhang Y, Jiang H and
He P: Matrine induces the apoptosis of lung cancer cells through
downregulation of inhibitor of apoptosis proteins and the Akt
signaling pathway. Oncol Rep. 32:1087–1093. 2014.PubMed/NCBI
|
|
23
|
Li H, Xie S, Liu X, Wu H, Lin X, Gu J,
Wang H and Duan Y: Matrine alters microRNA expression profiles in
SGC-7901 human gastric cancer cells. Oncol Rep. 32:2118–2126.
2014.PubMed/NCBI
|
|
24
|
Zhang S, Cheng B, Li H, Xu W, Zhai B, Pan
S, Wang L, Liu M and Sun X: Matrine inhibits proliferation and
induces apoptosis of human colon cancer LoVo cells by inactivating
Akt pathway. Mol Biol Rep. 41:2101–2108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang L, Wang T, Wen X, Wei Y, Peng X, Li
H and Wei L: Effect of matrine on HeLa cell adhesion and migration.
Eur J Pharmacol. 563:69–76. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J,
Zhang S, Wu J, Yu K and Han Y: Matrine induces apoptosis in human
acute myeloid leukemia cells via the mitochondrial pathway and Akt
inactivation. PLoS One. 7:e468532012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Y, Zhang ZN, Zhao HM, Tong ZC, Yang J,
Wang H and Liang XJ: Matrine inhibits the invasive properties of
human osteosarcoma cells by downregulating the ERK-NF-kB pathway.
Anticancer Drugs. 25:1035–1043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang S, Qi J, Sun L, Cheng B, Pan S, Zhou
M and Sun X: Matrine induces programmed cell death and regulates
expression of relevant genes based on PCR array analysis in C6
glioma cells. Mol Biol Rep. 36:791–799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie M, He G, Wang R, Shi S, Chen J, Ye Y,
Xie L, Yi X and Tang A: Matrine-induced apoptosis of human
nasopharyngeal carcinoma cells via in vitro vascular endothelial
growth factor-A/extracellular signal-regulated kinase1/2 pathway
inactivation. Horm Metab Res. 46:556–560. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Keith RL: Chemoprevention of lung cancer.
Proc Am Thorac Soc. 6:187–193. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saika K and Sobue T: Lung cancer: Progress
in diagnosis and treatments. Topics I. Epidemiology and
pathogenesis; 1. Epidemiology, prevention and screening. Nihon
Naika Gakkai Zasshi. 103:1255–1260. 2014.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nykainen A, Räsänen J, Salo J and Sihvo E:
Thoracoscopic surgery of lung cancer. Duodecim. 130:145–151.
2014.(In Finnish). PubMed/NCBI
|
|
33
|
Pflaum J, Schlosser S and Müller M: p53
family and cellular stress responses in cancer. Front Oncol.
4:2852014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Farnebo M, Bykov VJ and Wiman KG: The p53
tumor suppressor: A master regulator of diverse cellular processes
and therapeutic target in cancer. Biochem Biophys Res Commun.
396:85–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cadwell C and Zambetti GP: The effects of
wild-type p53 tumor suppressor activity and mutant p53
gain-of-function on cell growth. Gene. 277:15–30. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Marone M, Bonanno G, Rutella S, Leone G,
Scambia G and Pierelli L: Survival and cell cycle control in early
hematopoiesis: Role of bcl-2 and the cyclin dependent kinase
inhibitors P27 and P21. Leuk Lymphoma. 43:51–57. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saegusa M, Hashimura M, Suzuki E, Yoshida
T and Kuwata T: Transcriptional up-regulation of Sox9 by NF-kB in
endometrial carcinoma cells, modulating cell proliferation through
alteration in the p14 (ARF)/p53/p21 (WAF1) pathway. Am J Pathol.
181:684–692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dimitrova N, Zamudio JR, Jong RM, Soukup
D, Resnick R, Sarma K, Ward AJ, Raj A, Lee JT, Sharp PA and Jacks
T: LincRNA-p21 activates p21 in cis to promote Polycomb target gene
expression and to enforce the G1/S checkpoint. Mol Cell.
54:777–790. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen W, Yoshida S, Ohara N, Matsuo H,
Morizane M and Maruo T: Gonadotropin-releasing hormone antagonist
cetrorelix down-regulates proliferating cell nuclear antigen and
epidermal growth factor expression and up-regulates apoptosis in
association with enhanced poly (adenosine 5′-diphosphate-ribose)
polymerase expression in cultured human leiomyoma cells. J Clin
Endocrinol Metab. 90:884–892. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gao X, Dan S, Xie Y, Qin H, Tang D, Liu X,
He QY and Liu L: 14-3-3ζ reduces DNA damage by interacting with and
stabilizing proliferating cell nuclear antigen. J Cell Biochem.
116:158–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oyama T, Mitsudomi T, Mizoue T, Ohgami A,
Osaki T, Nakanishi R and Yasumoto K: Proliferating cell nuclear
antigen may be superior to argyrophilic nucleolar organizer regions
in predicting shortened survival of patients with non-small cell
lung cancer. Surg Oncol. 4:83–89. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sonenberg N: eIF4E, the mRNA cap-binding
protein: From basic discovery to translational research. Biochem
Cell Biol. 86:178–183. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Y, Fan S, Koo J, Yue P, Chen ZG,
Owonikoko TK, Ramalingam SS, Khuri FR and Sun SY: Elevated
expression of eukaryotic translation initiation factor 4E is
associated with proliferation, invasion and acquired resistance to
erlotinib in lung cancer. Cancer Biol Ther. 13:272–280. 2012.
View Article : Google Scholar : PubMed/NCBI
|
